XTL Biopharmaceuticals Ltd. is a biopharmaceutical company focused on the development, in-licensing, acquisition, and commercialization of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet medical needs. The Company is focused on developing therapeutics for the treatment of multiple myeloma (MM) and hepatitis C (HCV). XTL is publicly traded on the Tel Aviv Stock Exchange (TASE) and its ADRs are quoted Over-the-Counter on the Pink Sheets in the US (TASE: XTL, Pink Sheets: XTLBY).

Medicis Pharmaceutical Corporation is the leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatological and aesthetic conditions. Medicis is dedicated to helping patients attain a healthy and youthful appearance and self-image. Since our inception in 1988, we have introduced more than 25 new products and formulations, making us a prolific source of new products in the specialties we serve. Today, we have leading branded prescription products in a number of dermatological and aesthetic categories. Medicis products have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance. Medicis provides award-winning support to our physician-customers as they care for their patients and build their practices. We do this through new product development, growth of existing brands, strategic acquisitions, and collaborative relationships. Our goal is to maintain a strong leadership position in customer focus, both in dermatology and aesthetics, and other specialty fields we may enter.

BTG is an international specialty pharmaceuticals company that is developing and commercialising products targeting critical care, cancer, neurological and other disorders. The company is also seeking to acquire new products to develop and market to hospital specialists, and is building a sustainable business financed by revenues from sales of its critical care products and from royalties and milestone payments on partnered products.

BTG is an international specialty pharmaceuticals company that is developing and commercialising products targeting critical care, cancer, neurological and other disorders. The company is also seeking to acquire new products to develop and market to hospital specialists, and is building a sustainable business financed by revenues from sales of its critical care products and from royalties and milestone payments on partnered products.

Oxagen is a privately held biopharmaceutical company developing a pipeline of novel small molecule drugs to treat inflammatory and respiratory diseases. The company has created a portfolio of valuable drug targets centered on the highly attractive class of receptors, GPCRs. Through its heritage in human genetics, Oxagen has validated a number of GPCR targets, many of them novel, and is progressing the most promising as drug targets. The lead program, targeting a GPCR known as CRTH2 with a strong genetic association to asthma, has generated a number of promising candidate small molecules which are orally bioavailable and offer the potential to treat asthma and other respiratory and inflammatory conditions.

Abbott Laboratories (Abbott) is engaged in discovery, development, manufacture, and sale of diversified line of healthcare products. The Company operates in four segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Pharmaceutical Products include a line of adult and pediatric pharmaceuticals manufactured, marketed, and sold. Its Diagnostic Products include a line of diagnostic systems and tests manufactured, marketed, and sold to blood banks, hospitals, commercial laboratories, clinics, physicians' offices, alternate-care testing sites and plasma protein therapeutic companies. The Company’s Nutritional Products include a line of pediatric and adult nutritional products manufactured, marketed, and sold worldwide. Its Vascular Products include a line of coronary, endovascular, and vessel closure devices for the treatment of vascular disease manufactured, marketed and sold worldwide.